ChloroquineV1, Main, Exploration, bibRecord, 001513

Rituximab and lupus interstitial lung disease: friend or foe?

Identifieur interne : 001513 ( Main/Exploration ); précédent : 001512; suivant : 001514

Rituximab and lupus interstitial lung disease: friend or foe?

Auteurs : Petros Efthimiou ; Manil Kukar ; Alissa Hersh [États-Unis]

Source :

International Journal of Rheumatic Diseases [ 1756-1841 ] ; 2011-02.

RBID : ISTEX:ECF50A7A6A74993BB148D6A60B4ED1D23C5023BC

Descripteurs français

KwdFr :
- Acide mycophénolique (analogues et dérivés), Acide mycophénolique (usage thérapeutique), Adulte, Anticorps monoclonaux d'origine murine (usage thérapeutique), Antirhumatismaux (usage thérapeutique), Association de médicaments, Dyspnée (physiopathologie), Dyspnée (traitement médicamenteux), Dyspnée (étiologie), Facteurs immunologiques (usage thérapeutique), Glucocorticoïdes (usage thérapeutique), Humains, Hydroxychloroquine (usage thérapeutique), Lupus érythémateux disséminé (), Lupus érythémateux disséminé (traitement médicamenteux), Mâle, Pneumopathies interstitielles (physiopathologie), Pneumopathies interstitielles (traitement médicamenteux), Pneumopathies interstitielles (étiologie), Prednisolone (usage thérapeutique), Rituximab, Résultat thérapeutique, Syndrome de Gougerot-Sjögren (), Syndrome de Gougerot-Sjögren (traitement médicamenteux), Tests de la fonction respiratoire.
MESH :
- analogues et dérivés : Acide mycophénolique.
- physiopathologie : Dyspnée, Pneumopathies interstitielles.
- traitement médicamenteux : Dyspnée, Lupus érythémateux disséminé, Pneumopathies interstitielles, Syndrome de Gougerot-Sjögren.
- usage thérapeutique : Acide mycophénolique, Anticorps monoclonaux d'origine murine, Antirhumatismaux, Facteurs immunologiques, Glucocorticoïdes, Hydroxychloroquine, Prednisolone.
- étiologie : Dyspnée, Pneumopathies interstitielles.
- Adulte, Association de médicaments, Humains, Lupus érythémateux disséminé, Mâle, Rituximab, Résultat thérapeutique, Syndrome de Gougerot-Sjögren, Tests de la fonction respiratoire.

English descriptors

KwdEn :
- Adult, Antibodies, Monoclonal, Murine-Derived (therapeutic use), Antirheumatic Agents (therapeutic use), Drug Therapy, Combination, Dyspnea (drug therapy), Dyspnea (etiology), Dyspnea (physiopathology), Glucocorticoids (therapeutic use), Humans, Hydroxychloroquine (therapeutic use), Immunologic Factors (therapeutic use), Lung Diseases, Interstitial (drug therapy), Lung Diseases, Interstitial (etiology), Lung Diseases, Interstitial (physiopathology), Lupus Erythematosus, Systemic (complications), Lupus Erythematosus, Systemic (drug therapy), Male, Mycophenolic Acid (analogs & derivatives), Mycophenolic Acid (therapeutic use), Prednisolone (therapeutic use), Respiratory Function Tests, Rituximab, Sjogren's Syndrome (complications), Sjogren's Syndrome (drug therapy), Treatment Outcome.
MESH :
- chemical , analogs & derivatives : Mycophenolic Acid.
- chemical , therapeutic use : Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agents, Glucocorticoids, Hydroxychloroquine, Immunologic Factors, Mycophenolic Acid, Prednisolone.
- complications : Lupus Erythematosus, Systemic, Sjogren's Syndrome.
- drug therapy : Dyspnea, Lung Diseases, Interstitial, Lupus Erythematosus, Systemic, Sjogren's Syndrome.
- etiology : Dyspnea, Lung Diseases, Interstitial.
- physiopathology : Dyspnea, Lung Diseases, Interstitial.
Teeft :
- Adult, Drug Therapy, Combination, Erythematosus, Exercise tolerance, Humans, International journal, Interstitial pneumonitis, Lung disease, Lupus, Male, Pneumonitis, Respiratory Function Tests, Rheumatic diseases, Rituximab, Rituximab treatment, Systemic lupus erythematosus, Treatment Outcome.

Url:

https://api.istex.fr/ark:/67375/WNG-P4G2F80K-J/fulltext.pdf

DOI: 10.1111/j.1756-185X.2010.01592.x

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rituximab and lupus interstitial lung disease: friend or foe?</title>
<author><name sortKey="Efthimiou, Petros" sort="Efthimiou, Petros" uniqKey="Efthimiou P" first="Petros" last="Efthimiou">Petros Efthimiou</name>
</author>
<author><name sortKey="Kukar, Manil" sort="Kukar, Manil" uniqKey="Kukar M" first="Manil" last="Kukar">Manil Kukar</name>
</author>
<author><name sortKey="Hersh, Alissa" sort="Hersh, Alissa" uniqKey="Hersh A" first="Alissa" last="Hersh">Alissa Hersh</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:ECF50A7A6A74993BB148D6A60B4ED1D23C5023BC</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1111/j.1756-185X.2010.01592.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-P4G2F80K-J/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001322</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001322</idno>
<idno type="wicri:Area/Istex/Curation">001322</idno>
<idno type="wicri:Area/Istex/Checkpoint">000489</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000489</idno>
<idno type="wicri:doubleKey">1756-1841:2011:Efthimiou P:rituximab:and:lupus</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:21303472</idno>
<idno type="wicri:Area/PubMed/Corpus">000381</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000381</idno>
<idno type="wicri:Area/PubMed/Curation">000381</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000381</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000362</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000362</idno>
<idno type="wicri:Area/Ncbi/Merge">000153</idno>
<idno type="wicri:Area/Ncbi/Curation">000153</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000153</idno>
<idno type="wicri:Area/Main/Merge">001515</idno>
<idno type="wicri:Area/Main/Curation">001513</idno>
<idno type="wicri:Area/Main/Exploration">001513</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Rituximab and lupus interstitial lung disease: friend or foe?</title>
<author><name sortKey="Efthimiou, Petros" sort="Efthimiou, Petros" uniqKey="Efthimiou P" first="Petros" last="Efthimiou">Petros Efthimiou</name>
<affiliation></affiliation>
<affiliation><wicri:noCountry code="no comma">Weill Cornell Medical College</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kukar, Manil" sort="Kukar, Manil" uniqKey="Kukar M" first="Manil" last="Kukar">Manil Kukar</name>
<affiliation><wicri:noCountry code="subField">Center</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Hersh, Alissa" sort="Hersh, Alissa" uniqKey="Hersh A" first="Alissa" last="Hersh">Alissa Hersh</name>
<affiliation></affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Columbia University, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
<settlement type="city">New York</settlement>
</placeName>
<orgName type="university">Université Columbia</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">International Journal of Rheumatic Diseases</title>
<title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title>
<idno type="ISSN">1756-1841</idno>
<idno type="eISSN">1756-185X</idno>
<imprint><biblScope unit="vol">14</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="e3">e3</biblScope>
<biblScope unit="page" to="e4">e4</biblScope>
<biblScope unit="page-count">2</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2011-02">2011-02</date>
</imprint>
<idno type="ISSN">1756-1841</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1756-1841</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Antibodies, Monoclonal, Murine-Derived (therapeutic use)</term>
<term>Antirheumatic Agents (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Dyspnea (drug therapy)</term>
<term>Dyspnea (etiology)</term>
<term>Dyspnea (physiopathology)</term>
<term>Glucocorticoids (therapeutic use)</term>
<term>Humans</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Immunologic Factors (therapeutic use)</term>
<term>Lung Diseases, Interstitial (drug therapy)</term>
<term>Lung Diseases, Interstitial (etiology)</term>
<term>Lung Diseases, Interstitial (physiopathology)</term>
<term>Lupus Erythematosus, Systemic (complications)</term>
<term>Lupus Erythematosus, Systemic (drug therapy)</term>
<term>Male</term>
<term>Mycophenolic Acid (analogs & derivatives)</term>
<term>Mycophenolic Acid (therapeutic use)</term>
<term>Prednisolone (therapeutic use)</term>
<term>Respiratory Function Tests</term>
<term>Rituximab</term>
<term>Sjogren's Syndrome (complications)</term>
<term>Sjogren's Syndrome (drug therapy)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acide mycophénolique (analogues et dérivés)</term>
<term>Acide mycophénolique (usage thérapeutique)</term>
<term>Adulte</term>
<term>Anticorps monoclonaux d'origine murine (usage thérapeutique)</term>
<term>Antirhumatismaux (usage thérapeutique)</term>
<term>Association de médicaments</term>
<term>Dyspnée (physiopathologie)</term>
<term>Dyspnée (traitement médicamenteux)</term>
<term>Dyspnée (étiologie)</term>
<term>Facteurs immunologiques (usage thérapeutique)</term>
<term>Glucocorticoïdes (usage thérapeutique)</term>
<term>Humains</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Lupus érythémateux disséminé ()</term>
<term>Lupus érythémateux disséminé (traitement médicamenteux)</term>
<term>Mâle</term>
<term>Pneumopathies interstitielles (physiopathologie)</term>
<term>Pneumopathies interstitielles (traitement médicamenteux)</term>
<term>Pneumopathies interstitielles (étiologie)</term>
<term>Prednisolone (usage thérapeutique)</term>
<term>Rituximab</term>
<term>Résultat thérapeutique</term>
<term>Syndrome de Gougerot-Sjögren ()</term>
<term>Syndrome de Gougerot-Sjögren (traitement médicamenteux)</term>
<term>Tests de la fonction respiratoire</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Mycophenolic Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Murine-Derived</term>
<term>Antirheumatic Agents</term>
<term>Glucocorticoids</term>
<term>Hydroxychloroquine</term>
<term>Immunologic Factors</term>
<term>Mycophenolic Acid</term>
<term>Prednisolone</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Acide mycophénolique</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Lupus Erythematosus, Systemic</term>
<term>Sjogren's Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyspnea</term>
<term>Lung Diseases, Interstitial</term>
<term>Lupus Erythematosus, Systemic</term>
<term>Sjogren's Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyspnea</term>
<term>Lung Diseases, Interstitial</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Dyspnée</term>
<term>Pneumopathies interstitielles</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyspnea</term>
<term>Lung Diseases, Interstitial</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Dyspnée</term>
<term>Lupus érythémateux disséminé</term>
<term>Pneumopathies interstitielles</term>
<term>Syndrome de Gougerot-Sjögren</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acide mycophénolique</term>
<term>Anticorps monoclonaux d'origine murine</term>
<term>Antirhumatismaux</term>
<term>Facteurs immunologiques</term>
<term>Glucocorticoïdes</term>
<term>Hydroxychloroquine</term>
<term>Prednisolone</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Dyspnée</term>
<term>Pneumopathies interstitielles</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Adult</term>
<term>Drug Therapy, Combination</term>
<term>Erythematosus</term>
<term>Exercise tolerance</term>
<term>Humans</term>
<term>International journal</term>
<term>Interstitial pneumonitis</term>
<term>Lung disease</term>
<term>Lupus</term>
<term>Male</term>
<term>Pneumonitis</term>
<term>Respiratory Function Tests</term>
<term>Rheumatic diseases</term>
<term>Rituximab</term>
<term>Rituximab treatment</term>
<term>Systemic lupus erythematosus</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Association de médicaments</term>
<term>Humains</term>
<term>Lupus érythémateux disséminé</term>
<term>Mâle</term>
<term>Rituximab</term>
<term>Résultat thérapeutique</term>
<term>Syndrome de Gougerot-Sjögren</term>
<term>Tests de la fonction respiratoire</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>État de New York</li>
</region>
<settlement><li>New York</li>
</settlement>
<orgName><li>Université Columbia</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Efthimiou, Petros" sort="Efthimiou, Petros" uniqKey="Efthimiou P" first="Petros" last="Efthimiou">Petros Efthimiou</name>
<name sortKey="Kukar, Manil" sort="Kukar, Manil" uniqKey="Kukar M" first="Manil" last="Kukar">Manil Kukar</name>
</noCountry>
<country name="États-Unis"><region name="État de New York"><name sortKey="Hersh, Alissa" sort="Hersh, Alissa" uniqKey="Hersh A" first="Alissa" last="Hersh">Alissa Hersh</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001513 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001513 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:ECF50A7A6A74993BB148D6A60B4ED1D23C5023BC
   |texte=   Rituximab and lupus interstitial lung disease: friend or foe?
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

Serveur d'exploration Chloroquine

Rituximab and lupus interstitial lung disease: friend or foe?

Rituximab and lupus interstitial lung disease: friend or foe?

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.